A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  title={A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.},
  author={Soonmyung Paik and Steven Shak and Gong Tang and Chungyeul Kim and Joffre B. Baker and Maureen T. Cronin and Frederick L. Baehner and Michael G. Walker and Drew Watson and Taesung Park and William Hiller and Edwin R. Fisher and D. Lawrence Wickerham and John Bryant and Norman Wolmark},
  journal={The New England journal of medicine},
  volume={351 27},
BACKGROUND The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures. METHODS We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated… 

Figures and Tables from this paper

Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy

RT-PCR can be done on paraffin-embedded tissue to validate the large numbers of genes associated with breast cancer recurrence, however, further work needs to be done to develop an assay to identify the likelihood of recurrent disease in patients with node-negative breast cancer who do not receive adjuvant tamoxifen or chemotherapy.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy.

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes

Tumor gene expression profiles of archival tissues provide significant information about risk of distant recurrence even among patients with 10 or more nodes, and several genes, including TP53BP2 and Bcl2, as significant predictors of DRFS.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Either the GG assay or centrally reviewed Ki67 significantly improves clinicopathological models to determine distant recurrence of breast cancer.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.

Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.

A prospective study to examine whether chemotherapy is required for the intermediate-risk group defined by the RS is accruing in North America, and whether high-risk patients identified with the RS preferentially benefit from chemotherapy.

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.

The Trial Assessing IndiviuaLized Options for Treatment for breast cancer, a randomized trial of chemotherapy followed by hormonal therapy versus hormonal therapy alone on invasive disease-free survival-ductal carcinoma in situ (IDFS-DCIS) survival in women with node-negative, estrogen-receptor-positive breast cancer with a recurrence score of 11-25 is developed.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

  • L. GoldsteinR. Gray J. Sparano
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
The 21-gene assay was a more accurate predictor of relapse than standard clinical features for individual patients with HR-positive operable breast cancer treated with chemohormonal therapy and provides information that is complementary to features typically used in anatomic staging, such as tumor size and lymph node involvement.



Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer

Whether the RS assay predicts prognosis, response to tamoxifen, or both, is determined, and a subset of individual genes (Cyclin B1, Survivin, MYBL2, STK15, Ki-67, PR, and GSTM1), the proliferation gene group score and the RS were significantly associated with DRFS in the placebo pts.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  • L. GianniM. Zambetti S. Shak
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Quantitative expression of ER-related genes, proliferation genes, and immune- related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel, suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit.

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer

A well-defined cohort of over 4000 breast cancer patients from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-14 who had ER-positive tumors and no axillary lymph-node involvement was analyzed, and a strong association was found between S-phase fraction and DFS, as well as survival.

Gene expression profiling predicts clinical outcome of breast cancer

DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.

Prognostic molecular markers in early breast cancer

The role of established molecular markers, as well as potential applications of emerging new technologies, are discussed, including markers of proliferation, hormone receptors, and the human epidermal growth factor receptor 2.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

AbstractBackground. Researchers question whether estrogen receptorα-negative (ERN) and -positive (ERP) represent different stages of one disease or different breast cancer types. Objective. To

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation and was attained with a low incidence of clinically appreciable toxic effects.